SCHEMBL10076074

SCHEMBL10076074

CCC(=O)N[C@@H](C(=O)O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
PLA2G2A P14555 1/20 0.49
PLA2G5 P39877 1/20 0.49
SDCBP O00560 3/20 0.46
SDC2 P34741 3/20 0.46
CYP2C9 P11712 1/20 0.45
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
MBTPS1 Q14703 1/20 0.43
EPHX2 P34913 1/20 0.41
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946709 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4182518 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL22128039 0.85 CYP2C9 (0.41) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL22128037 0.85 CYP2C9 (0.41) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL30569794 0.85 PSMB5 (0.49) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4195957 0.84 CYP2C9 (0.43) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4195960 0.84 CYP2C9 (0.43) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5
SCHEMBL4186736 0.83 ALDH1A1 (0.63) ALDH1A1CYP2C9
SCHEMBL4186738 0.83 ALDH1A1 (0.63) ALDH1A1CYP2C9
SCHEMBL1734627 0.83 PLA2G2A (0.54) ALDH1A1SMN1; SMN2NPSR1PLA2G2APLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013161980-A1 CYCLOHEXANEDIAMIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES 東レ株式会社 (JP) 2013-10-31 WO disclosed
EP-1697354-B1 ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS MERCK SHARP & DOHME (US) 2013-08-07 EP disclosed
US-8093231-B2 Sulfonylethyl phosphorodiamidates TELIK, INC. (US) 2012-01-10 US disclosed
US-20080039429-A1 SULFONYLETHYL PHOSPHORODIAMIDATES TELIK, INC. 2008-02-14 US disclosed
US-7262182-B2 Sulfonylethyl phosphorodiamidates TELIK, INC. (US) 2007-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039429-A1 SULFONYLETHYL PHOSPHORODIAMIDATES MTAP, TYMP, PHOSPHO1 ALDH1A1 4455/4885SMN1; SMN2 1097/4885NPSR1 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.